Treatment-resistant depression, how TMS therapy actually works, how to verify your insurance, what to expect during your first session. Written for patients and families.
How transcranial magnetic stimulation is used off-label for the depressive phase of bipolar I and II disorder — when it is clinically appropriate, why adequate mood-stabilizer therapy and monitoring are prerequisites, and the protocol considerations that differ from unipolar depression.
Why transcranial magnetic stimulation is a reasonable, lactation-compatible option for postpartum depression when first-line treatment falls short or systemic medication is declined — an off-label use of an FDA-cleared therapy that acts focally, with nothing transferred into breast milk.
Where transcranial magnetic stimulation fits for PTSD after first-line treatments fall short — an off-label use of an FDA-cleared therapy, the controlled-trial and meta-analysis evidence, and why the strongest signal appears in patients whose PTSD co-occurs with depression.
The FDA-cleared Deep TMS option for OCD when SSRIs and Exposure and Response Prevention haven't brought enough relief — how the H7 coil targets the medial prefrontal and anterior cingulate cortex, the standard protocol, and the response rates patients can expect.
How psychiatrists define treatment-resistant depression when one or two antidepressants haven't worked, what the evidence shows about remission after sequential medication trials, and where FDA-cleared neuromodulation options like TMS fit in the treatment pathway.
Insurance verification takes about two minutes. We'll tell you whether your plan covers TMS for treatment-resistant depression and what your cost will be — before you book anything.
Monday–Friday, 9:00 AM – 5:00 PM